Skip to main content
ANI Pharmaceuticals Logo
  • About
    • Executive Team
    • Board of Directors
    • How We Operate
      Quality Capabilities
    • Locations
    • News
  • Products
  • Contract Manufacturing
  • Investors
  • Careers
    • Careers
    • Benefits
    • Available Positions
    • Application
  • Contact
    • Contact Us
    • Locations

News

  • Overview
    • News
    • Events & Presentations
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Investment Calculator
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Governance
      • Governance Documents
      • Executive Management
      • Board of Directors
      • Committee Composition
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts

Site Search

Normal
Press release year list 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 2008
05/20/2022
ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
05/10/2022
ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million
04/19/2022
ANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022
04/11/2022
ANI Pharmaceuticals Announces the Launch of Misoprostol Tablets
03/22/2022
ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors
03/15/2022
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth
03/07/2022
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
02/24/2022
ANI Pharmaceuticals Strengthens Rare Disease Business Unit Leadership Team
01/24/2022
ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) for Multiple Chronic Autoimmune Disorders
01/03/2022
ANI Pharmaceuticals to Present at the H.C. Wainwright Bioconnect Virtual Conference

Contact Us

INVESTOR CONTACT

In-Site Communications, Inc.
Lisa M. Wilson

212-452-2793
IR@anipharmaceuticals.com

Quick Links

  • SEC Filings
  • Investor FAQs
  • Information Request Form

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At ANI Pharmaceuticals, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to ANI Pharmaceuticals to send you the requested Investor Email Alert updates.

* Required

*
*





 
Enter the code shown above.
Unsubscribe

Email Alert Sign Up Confirmation

ANI Pharmaceuticals Logo
  • Products
  • Investors
  • Careers
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Accessibility
© Copyright ANI Pharmaceuticals, Inc.
  • follow us on linkedin
  • follow us on youtube
Powered By Q4 Inc. 5.71.0.1 (opens in new window)